VXM01
Glioblastoma, Pancreatic Cancer, other solid tumors
Phase 1/2Active
Key Facts
Indication
Glioblastoma, Pancreatic Cancer, other solid tumors
Phase
Phase 1/2
Status
Active
Company
About Vaximm
Vaximm is pioneering an innovative oral immunotherapy platform that activates cytotoxic T-cells to fight solid tumors, differentiating itself through its non-invasive administration route. The company has built a pipeline targeting clinically-validated tumor-associated antigens, with its lead program in glioblastoma having reached Phase 1/2 clinical testing. Founded by renowned immunologists and headquartered in Basel, Switzerland, Vaximm operates as a private, preclinical to early clinical-stage biotech seeking to address significant unmet needs in oncology. Its strategy hinges on demonstrating proof-of-concept for oral T-cell vaccines to attract partnership and further investment.
View full company profile